Share on StockTwits

Charles River Laboratories (NYSE:CRL)‘s stock had its “neutral” rating reiterated by research analysts at Credit Suisse in a report released on Friday. They currently have a $60.00 price target on the stock, up from their previous price target of $56.00. Credit Suisse’s target price suggests a potential upside of 6.19% from the company’s current price.

CRL has been the subject of a number of other recent research reports. Analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Charles River Laboratories in a research note on Tuesday, May 20th. They now have a $60.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $57.56.

Charles River Laboratories (NYSE:CRL) traded up 0.51% on Friday, hitting $56.79. 547,798 shares of the company’s stock traded hands. Charles River Laboratories has a one year low of $44.12 and a one year high of $62.50. The stock has a 50-day moving average of $53.70 and a 200-day moving average of $56.00. The company has a market cap of $2.666 billion and a P/E ratio of 23.11.

Charles River Laboratories (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 16.5% on a year-over-year basis. Analysts expect that Charles River Laboratories will post $3.23 EPS for the current fiscal year.

Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.